Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-02-07
2006-02-07
Cook, Rebecca (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
06995173
ABSTRACT:
Methods and compositions for treating specific patient groups for Central Nervous System disorders, including but not limited to Tourette Syndrome, are provided. The methods of the present invention comprise the utilization of pharmaceutical compositions comprising quinolinones (and derivatives thereof) in patients with symptoms of a Central Nervous System Disorder who are otherwise free of cardiac disease and/or who have not been given organic nitrates.
REFERENCES:
patent: 4277479 (1981-07-01), Nishi et al.
patent: 4302460 (1981-11-01), Davies et al.
patent: 4522884 (1985-06-01), Brody
patent: 4552891 (1985-11-01), Ho et al.
patent: 4623650 (1986-11-01), Gilligan et al.
patent: 4710506 (1987-12-01), Davies et al.
patent: 4772614 (1988-09-01), Davies et al.
patent: 4855291 (1989-08-01), Davies
patent: 4877793 (1989-10-01), Davies
patent: 4997840 (1991-03-01), Davies et al.
patent: 5011931 (1991-04-01), MacLean et al.
patent: 5079264 (1992-01-01), MacLean et al.
patent: 5393773 (1995-02-01), Craig et al.
patent: 5554639 (1996-09-01), Craig et al.
patent: 5627191 (1997-05-01), Birch et al.
patent: 5670539 (1997-09-01), Richardson et al.
patent: 5686473 (1997-11-01), Cosford et al.
patent: 5731314 (1998-03-01), Bencherif et al.
patent: 5767116 (1998-06-01), Kerrigan et al.
patent: 5801161 (1998-09-01), Merkus
patent: 5864037 (1999-01-01), Chasin et al.
patent: 5869479 (1999-02-01), Kreutner et al.
patent: WO 94/02144 (1994-02-01), None
MEDLINE AN 1999005735, Torigoe et al, No To Shinkei, Brain and Nerve, Sep. 1998 50(9) 8299-39, abstract.
BIOSIS AN 1993:98778, Ikezone et al, Arzneimittl-Forschung, 1992 42(10) 1200-1211, abstract.
McMurry,Organic Chemistry, 2nd Ed., Brooks/Cole Publishing, Belmont, CA (1988), pp. 1044-1045 and 1076.
Kelso et al., “Actions of the Novel Vasodilator, Flosequinan, in Isolated Ventricular Cardiomyocytes,”J. Cardiovasc. Pharmacol.25:376-386 (1995).
Perreault et al., “Differential inotropic effects of flosequinan in ventricular muscle from noemal ferrets versus patients with end-stage heart failure,”Br. J. Pharmacol.106:511-516 (1992).
Jones et al., “Effect of flosequinan on ischaemia-induced arrhythmias and on ventricular cyclic nucleotide content in the anaestetized rat,”Br. J. Pharmacol.108:1111-1116 (1993).
Gristwood et al., “Studies on the cardiac actions of flosequinan in vitro,”Br. J. Pharmacol.105:985-991 (1992).
Frodsham et al., “Effect of flosequinan upon isoenzymes of phosphodiesterase from guinea-pig cardiac and vascular smooth muscle,”Eur. J. Pharmacol.211:383-391 (1992).
Dawson et al., “Cilostazol Has Beneficial Effects in Treatment of Intermittent Claudication”,Circulation98:678-686 (1998).
Elam et al., “Effect of the Novel Antiplatelet Agent Cilostazol on Plasma Lipoproreins in Patients with Intermittent Claudication,”Arterioscler Thromb. Vasc. Biol.18:1942-1947 (1998).
Drug Evaluation Monographs, vol. 99, Micromedex Inc. (1999).
Nishi et al., “Studies on 2-Oxoquinoline Derivatives as Blood Platelet Aggregation Inhibitors. II. 6-[3-(1-Cyclohexyl-5-tetrazolyl)propoxy]-1,2-dihydro-2-oxoquinoline and Related Compounds,”Chem. Pharm. Butl.31:1151-1157 (1983).
Shimizu, T. et al., “Physico-chemical Properties and Stability of Cilostazol,”Arzneim.-Forsch.35:1117-1208 (1985).
Suri et al., “Pharmacolinetics of Multiple-Dose Oral Cilostazol in Middle-Age and Elderly Men and Women,”J. Clin. Pharmacol.38:144-150 (1998).
Niki and Mori, “Phase I Study od Cilostazol,”Arzneim.-Forsch35:1173-1185 (1985).
Watkins, CC et al. “Insulin restores neuronal nitric oxide synthase expression and function that is lost in diabetic gastropathy”J Clin Invest106:373-384 (2000).
Moreira et al., “Side-effect profile of sildenafil citrate (Viagra) in clinical practice,”Urology, 56(3):474-76 (2000).
Morita et al., “Synthesis and Absolute Configuration of the Enantiomers of 7-Fluoro-1-methyl-3(methylsulfiny)-4(1H)-quinolonone (Flosequinan).”Chem. Pharm. Bull.42(10):2157-2160 (1994).
Robertson M., “Tourette Syndrome, associated conditions and the complexities of treatment,”Brain123:425, 427 (2000).
Juncos, J. and Delong, M., “Parkinson's disease and basal ganglia movement disorders”, inScientific American Medicine, Rubinstien and Federman eds., Ch. 11, pp. XV-1 to XV-19 (1997).
Cutler Neal R.
Sramek John
Cook Rebecca
Medlen & Carroll LLP
R.T. Alamo Ventures I, LLC
LandOfFree
Methods for the treatment of central nervous system... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for the treatment of central nervous system..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for the treatment of central nervous system... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3685349